OUTPACE Trademark

Trademark Overview


On Friday, January 17, 2025, a trademark application was filed for OUTPACE with the United States Patent and Trademark Office. The USPTO has given the OUTPACE trademark a serial number of 99007123. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Wednesday, January 7, 2026. This trademark is owned by Outpace Bio, Inc.. The OUTPACE trademark is filed in the Pharmaceutical Products category with the following description:

Therapeutics for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; cell therapies, in the nature of modified cells, engineered cells, therapeutic agents, and their delivery agents, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; biopharmaceuticals for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; medicines for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; medical preparations for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metaboli...
outpace

General Information


Serial Number99007123
Word MarkOUTPACE
Filing DateFriday, January 17, 2025
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateWednesday, January 7, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesTherapeutics for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; cell therapies, in the nature of modified cells, engineered cells, therapeutic agents, and their delivery agents, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; biopharmaceuticals for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; medicines for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; medical preparations for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical products for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; therapeutic pharmaceuticals for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; therapeutic agents for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; biologics in the nature of cells for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; biologics in the nature of viral vectors for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; biologic preparations for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; cells for medical or clinical purposes; viral or non-viral delivery vectors, namely, delivery agents for treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; therapeutic proteins for medical or clinical purposes; antibodies and libraries of antibodies for medical purposes; pharmaceutical preparations for cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorder, and genetic disorders; pharmaceutical preparations for targeted cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical products for cellular therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; gene therapy products, namely, genetically engineered cells, cell components, molecules, proteins and protein complexes; therapeutic preparations, namely, therapeutic antigens for medical purposes and antibodies for medical purposes; engineered cells for medical use; bioengineered cells for medical use; biological preparations for use in cell engineering platforms cultures for medical purposes; biological preparations for use in protein design platforms for medical purposes; biological preparations designed by computational protein design platforms for medical purposes; biological preparations designed by AI-powered protein design platforms for medical purposes; pharmaceutical preparations developed with a computational protein design platform for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations developed with AI-powered protein design platforms for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders; pharmaceutical preparations for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of cells, cell components, molecules, and viruses for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of gene delivery vectors for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of proteins for medical or clinical purposes, in particular for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders;

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, January 17, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameOutpace Bio, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeattle, WA 98109

Trademark Events


Event DateEvent Description
Friday, January 17, 2025NEW APPLICATION ENTERED
Friday, January 17, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, June 27, 2025ASSIGNED TO EXAMINER
Monday, July 7, 2025NON-FINAL ACTION WRITTEN
Monday, July 7, 2025NON-FINAL ACTION E-MAILED
Monday, July 7, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, October 6, 2025APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Monday, October 6, 2025APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Tuesday, January 6, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 6, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 7, 2026TEAS/EMAIL CORRESPONDENCE ENTERED